Moran Wealth Management LLC Raises Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX

Moran Wealth Management LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 442.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 168,961 shares of the biopharmaceutical company’s stock after acquiring an additional 137,791 shares during the period. Moran Wealth Management LLC’s holdings in Catalyst Pharmaceuticals were worth $4,183,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Fundsmith LLP increased its holdings in shares of Catalyst Pharmaceuticals by 24.2% in the third quarter. Fundsmith LLP now owns 3,363,807 shares of the biopharmaceutical company’s stock worth $66,267,000 after purchasing an additional 654,721 shares during the period. Kennedy Capital Management LLC raised its position in shares of Catalyst Pharmaceuticals by 5.0% in the third quarter. Kennedy Capital Management LLC now owns 1,060,207 shares of the biopharmaceutical company’s stock worth $20,886,000 after buying an additional 50,746 shares in the last quarter. WINTON GROUP Ltd boosted its stake in Catalyst Pharmaceuticals by 546.7% during the fourth quarter. WINTON GROUP Ltd now owns 353,529 shares of the biopharmaceutical company’s stock valued at $8,251,000 after buying an additional 298,862 shares during the period. Wakefield Asset Management LLLP bought a new stake in Catalyst Pharmaceuticals during the fourth quarter valued at $1,203,000. Finally, Merit Financial Group LLC purchased a new position in Catalyst Pharmaceuticals during the fourth quarter worth about $654,000. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, March 25th. Zacks Research lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Finally, Robert W. Baird cut shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $31.45 on Friday. The stock has a market cap of $3.85 billion, a P/E ratio of 18.07, a P/E/G ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $32.56. The stock’s fifty day moving average price is $30.93 and its 200-day moving average price is $26.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).